Table 2 Main characteristics of randomized controlled trials included in the meta-analysis
Study ID | Area | Operation period | Study design | Surgery type | No. of patients (PP/control) | Age (years) | Male (%) | Cross-clamp time (min) | CPB time (min) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PP | Control | PP (%) | Control (%) | PP | Control | PP | Control | ||||||
Kaya [34] | Turkey | 2012.3–2013.1 | RCT | CABG | 63(30/33) | 57 ± 10 | 59 ± 11 | 76.67 | 87.88 | 43 ± 16 | 46 ± 21 | 80 ± 26 | 86 ± 27 |
Kaygin [33] | Turkey | 2009.8–2011.2 | RCT | CABG | 425(213/212) | 59 ± 11 | 59 ± 11 | 50.23 | 49.53 |  > 50 |  > 50 |  > 80 |  > 80 |
Fawzy [35] | Egypt | 2010.6–2012.5 | RCT | CABG | 200(100/100) | 54 ± 9 | 56 ± 10 | 64.00 | 68.00 | 55 ± 21 | 59 ± 17 | 89 ± 29 | 87 ± 23 |
Zhao [29] | China | 2012.1–2013.1 | RCT | CABG | 458(228/230) | 54 ± 16 | 56 ± 18 | 60.53 | 54.35 | 67 ± 29 | 62 ± 23 | 110 ± 46 | 103 ± 51 |
Kuralay [18] | Turkey | 1996.6–1997.6 | RCT | CABG | 200(100/100) | 57 ± 12 | 61 ± 8 | 77 | 73 | 36 ± 12 | 43 ± 9 | 48 ± 5 | 51 ± 4 |
Asimakopoulos [32] | UK | NR | RCT | CABG | 100(50/50) | 60 ± 9 | 60 ± 9 | NR | NR | 35 | 33 | 66 | 62 |
Ekim [20] | Turkey | 2003.10–2005.7 | RCT | CABG | 100(50/50) | 59 ± 9 | 60 ± 3 | 66 | 64 | 63 ± 19 | 62 ± 12 | 89 ± 21 | 87 ± 26 |
Farsak [19] | Turkey | 2000.4–2001.10 | RCT | CABG | 150(75/75) | 64 ± 9 | 63 ± 5 | 36 | 32 | 35 ± 11 | 40 ± 9 | 58 ± 6 | 61 ± 9 |
Kongmalai [22] | Thailand | 2013.8–2013.12 | RCT | CABG | 20(10/10) | 65 ± 13 | 59 ± 5 | 50.00 | 50.00 | 84 ± 38 | 107 ± 39 | 128 ± 49 | 152 ± 45 |
Arbatli [21] | Turkey | 2000.5–2000.12 | RCT | CABG | 113(54/59) | 62 ± 8 | 60 ± 9 | 83.33 | 74.58 | 58 ± 17 | 60 ± 19 | 117 ± 32 | 112 ± 35 |